Tag: sites

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Learn key insights from the 2025 "State of the Air" report and how Camfil’s IAQ solutions address air quality challenges for healthier indoor spaces.

From Glamping and RVing to Nostalgic Tent Camping, Kampgrounds Of America Shares What’s New, What’s Trending, And How Camping Continues To Evolve

COMMUNIQUÉ DE PRESSE

Rare Fully-Entitled Luxury Development Sites in Beverly Hills Hits Market, Offering 89 New Units in one of Nation’s Tightest Land Markets

ARGYLE, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Enclave at Hickory Hill, is coming soon to Argyle, Texas. This exclusive Dallas-area community will feature new luxury homes on spacious one-acre home sites, offering an exceptional living experience in Denton County. Site work is underway, and the community is anticipated to open for sale in fall 2025.